An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms INJECZTRA
- Sponsors LEO Pharma
- 12 Jan 2024 According to a LEO Pharma media release, the company will present data at the upcoming Winter Clinical and Maui Derm conferences this month. The 2024 Winter Clinical Conference will take place Jan. 12-17 in Honolulu, Hawaii, while Maui Derm is being held from Jan. 22-26 in Maui, Hawaii.
- 17 Aug 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Planned End Date changed from 20 Oct 2023 to 4 Aug 2023.